ERBB2 and neoplasm: In line with this, Xiao et al. developed a trastuzumab-sialidase conjugate that selectively removes Neu5Ac moieties from ErbB2-expressing tumor cells, as well as ErbB2-negative neighboring cells, immunoediting their glycocalyx and increasing tumor cell vulnerability to ADCC [90].